A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 233,261 shares of GILD stock, worth $19.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
233,261
Holding current value
$19.4 Million
% of portfolio
0.05%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $14.7 Million - $17 Million
233,261 New
233,261 $16 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $2.71 Million - $3.08 Million
37,031 Added 14.86%
286,270 $23.2 Million
Q3 2023

Nov 13, 2023

SELL
$73.94 - $80.67 $1.52 Million - $1.66 Million
-20,565 Reduced 7.62%
249,239 $18.7 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $1.51 Million - $1.72 Million
-19,880 Reduced 6.86%
269,804 $20.8 Million
Q1 2023

May 12, 2023

BUY
$77.31 - $88.08 $3.46 Million - $3.94 Million
44,704 Added 18.25%
289,684 $24 Million
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $18.6 Million - $26.8 Million
-299,016 Reduced 54.97%
244,980 $21 Million
Q3 2022

Nov 10, 2022

SELL
$59.54 - $68.01 $2.14 Million - $2.44 Million
-35,900 Reduced 6.19%
543,996 $33.6 Million
Q2 2022

Aug 12, 2022

BUY
$57.72 - $65.01 $5.26 Million - $5.93 Million
91,200 Added 18.66%
579,896 $35.8 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $4.33 Million - $5.42 Million
74,696 Added 18.04%
488,696 $29.1 Million
Q4 2021

Feb 11, 2022

SELL
$64.88 - $73.64 $123,271 - $139,916
-1,900 Reduced 0.46%
414,000 $30.1 Million
Q3 2021

Nov 12, 2021

BUY
$67.69 - $73.03 $2.94 Million - $3.17 Million
43,400 Added 11.65%
415,900 $29.1 Million
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $5.62 Million - $6.14 Million
88,600 Added 31.21%
372,500 $25.7 Million
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $6.53 Million - $7.45 Million
108,870 Added 62.2%
283,900 $18.3 Million
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $5.31 Million - $6.05 Million
93,700 Added 115.21%
175,030 $10.2 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $6,210 - $7,808
100 Added 0.12%
81,330 $5.14 Million
Q2 2020

Aug 13, 2020

BUY
$72.34 - $84.0 $2.28 Million - $2.64 Million
31,461 Added 63.21%
81,230 $6.25 Million
Q1 2020

May 14, 2020

SELL
$62.63 - $80.22 $7.68 Million - $9.84 Million
-122,655 Reduced 71.14%
49,769 $3.72 Million
Q4 2019

Feb 13, 2020

SELL
$61.62 - $67.78 $2.59 Million - $2.85 Million
-42,076 Reduced 19.62%
172,424 $11.2 Million
Q3 2019

Nov 13, 2019

SELL
$62.51 - $69.0 $2.39 Million - $2.64 Million
-38,300 Reduced 15.15%
214,500 $13.6 Million
Q2 2019

Aug 13, 2019

BUY
$61.87 - $69.38 $426,903 - $478,721
6,900 Added 2.81%
252,800 $17.1 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $15.4 Million - $17.2 Million
245,900 New
245,900 $16 Million
Q3 2018

Nov 14, 2018

SELL
$71.28 - $78.92 $684,288 - $757,632
-9,600 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $19,464 - $22,704
300 Added 3.23%
9,600 $680,000
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $661,695 - $776,736
9,300 New
9,300 $666,000
Q3 2017

Nov 14, 2017

SELL
$72.11 - $85.47 $490,348 - $581,196
-6,800 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
6,800
6,800 $481,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $104B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track Jeremy Grantham's Portfolio

Track Jeremy Grantham Portfolio

Follow Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.